Latest Trials Latest NewsFAQ

Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

Phase 2

Completed

Conditions: Overweight
Obesity

Interventions: Drug: NNC0174-0833
Drug: Placebo (NNC0174-0833)
Drug: Placebo (Liraglutide 3.0 mg)
Drug: Liraglutide 3.0 mg

First Posted Date: 2019-02-27

Last Posted Date: 2024-07-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 706

Registration Number: NCT03856047

Locations: 🇺🇸
South Broward Research LLC, Pembroke Pines, Florida, United States
🇺🇸
Spartanburg Medical Research, Spartanburg, South Carolina, United States
🇺🇸
Texas Diabetes & Endocinology, Round Rock, Texas, United States

and more 50 locations

A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2

Phase 2

Completed

Conditions: Primary Hyperoxaluria Type 2 (PH2)
Genetic Disease
Kidney Diseases
Urologic Diseases
Primary Hyperoxaluria Type 1 (PH1)

Interventions: Drug: DCR-PHXC
Drug: Sterile Normal Saline (0.9% NaCl)

First Posted Date: 2019-02-20

Last Posted Date: 2024-05-22

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 35

Registration Number: NCT03847909

Locations: 🇬🇧
Clinical Trial Site, London, United Kingdom

A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity

Phase 1

Completed

Conditions: Overweight
Obesity

Interventions: Drug: Semaglutide
Drug: Placebo

First Posted Date: 2019-02-15

Last Posted Date: 2020-12-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 72

Registration Number: NCT03842202

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin degludec/liraglutide

First Posted Date: 2019-01-30

Last Posted Date: 2021-09-22

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 300

Registration Number: NCT03823339

Locations: 🇦🇪
Novo Nordisk Investigational Site, Dubai, United Arab Emirates

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo (semaglutide)
Drug: Semaglutide

First Posted Date: 2019-01-28

Last Posted Date: 2024-08-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 3508

Registration Number: NCT03819153

Locations: 🇺🇸
Alliance for Multispec Res, Norman, Oklahoma, United States
🇺🇸
Juno Research, LLC_Houston, Houston, Texas, United States
🇺🇸
Oceane 7 Medical & Research Center, Inc., Miami, Florida, United States

and more 402 locations

Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Fast-acting insulin aspart
Device: iLet™

First Posted Date: 2019-01-25

Last Posted Date: 2020-06-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT03816761

Locations: 🇺🇸
Novo Nordisk Investigational Site, Boston, Massachusetts, United States

A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)

Phase 3

Active, not recruiting

Conditions: Growth Hormone Deficiency in Children

Interventions: Drug: Somapacitan
Drug: Norditropin®

First Posted Date: 2019-01-22

Last Posted Date: 2024-11-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 200

Registration Number: NCT03811535

Locations: 🇸🇮
University Children's Hospital, Ljubljana, Slovenia
🇺🇸
Univ of AL at Birmingham_BRM, Birmingham, Alabama, United States
🇺🇸
Children's Hospital Los Angeles - Endocrinology, Los Angeles, California, United States

and more 93 locations

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

Phase 3

Active, not recruiting

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide
Drug: Placebo (semaglutide)

First Posted Date: 2019-01-22

Last Posted Date: 2024-11-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1500

Registration Number: NCT03811561

Locations: 🇺🇸
Diabetes/Lipid Mgmt & Res Ctr, Huntington Beach, California, United States
🇸🇰
Nemocnica akademika L. Derera, UNB, Bratislava, Slovakia
🇺🇸
Del Sol Research Management, LLC, Tucson, Arizona, United States

and more 170 locations

STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity

Phase 3

Completed

Conditions: Overweight
Obesity

Interventions: Drug: Placebo (semaglutide)
Drug: Semaglutide

First Posted Date: 2019-01-22

Last Posted Date: 2022-03-22

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 401

Registration Number: NCT03811574

Locations: 🇰🇷
Novo Nordisk Investigational Site, Yangsan, Korea, Republic of

An International Survey of the Occurrence of Cardiovascular Disease Among Patients With Type 2 Diabetes

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Other: No treatment given

First Posted Date: 2019-01-22

Last Posted Date: 2020-06-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 7548

Registration Number: NCT03811288

Locations: 🇹🇷
Novo Nordisk Investigational Site, Zonguldak, Turkey

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy